Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib

Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated anti‐MM activity in preclinical studies and encouraging early‐phase clinical activity in combination with bortezo...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G., Nagler, Arnon, Ben‐Yehuda, Dina, Badros, Ashraf, Hari, Parameswaran N., Hajek, Roman, Spicka, Ivan, Kaya, Hakan, LeBlanc, Richard, Yoon, Sung‐Soo, Kim, Kihyun, Martinez‐Lopez, Joaquin, Mittelman, Moshe, Shpilberg, Ofer, Blake, Paul, Hideshima, Teru, Colson, Kathleen, Laubach, Jacob P., Ghobrial, Irene M., Leiba, Merav, Gatt, Moshe E., Sportelli, Peter, Chen, Michael, Anderson, Kenneth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematologic Malignancy–Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175725/
https://www.ncbi.nlm.nih.gov/pubmed/35847734
http://dx.doi.org/10.1002/jha2.4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175725/
https://www.ncbi.nlm.nih.gov/pubmed/35847734
http://dx.doi.org/10.1002/jha2.4

Ejemplares similares